Table 4.
Multimarker panels that discriminate ovarian cancer cases from healthy controls.
| Panel | Cases/controls | SN/SP | Analytical platform | Bioinformatics method | Biomarker prioritization | Year | Ref. |
|---|---|---|---|---|---|---|---|
| CA-125, ApoA1, TTR | 200/142† | 74/97 | MS | SVM | No | 2004 | [61] |
| CA-125, CA 72–4, MCSF | 123/224† | 70/98 | ELISA | CT, MDA, LR | Yes | 2004 | [59] |
| CA-125, IL-6, IL-8, VEGF, EGF | 44/45 | 85/95 | BBIA | CT | No | 2005 | [144] |
| CA-125, TTR, ApoA1 | 20/82 | 89/92 | MS | LR | No | 2007 | [119] |
| CA-125, leptin, PRL, OPN, IGF-II, MIF | 156/362† | 95.3/99.4 | BBIA | LR | No | 2008 | [60] |
| CA-125, HE4, glycodelin, cPlau-R, MUC1, PAI1 | 200/396 | 80–89/87 | BBIA | LR | Yes | 2008 | [124] |
| CA-125, HE4, CEA, VCAM-1 | 456/2000† | 86–93/98 | BBIA | MMC | No | 2010 | [54,12] |
| CA-125, CA 19–9, EGFR, CRP, myoglobin, Apo A1, CIII, MIP1a, IL-6, IL-18, tenascin C | 176/187† | 91.3/88.5 | BBIA | Knowledge Discovery Engine-VS | No | 2008, 2009 | [52,57] |
| CA-125, CRP, SAA, IL-6, IL-8 | 150/212† | 94.1/91.3 | BBIA | LR | Yes | 2010 | [58] |
| CA-125, HE4, SI | 74/137 | 84/98.5 | ELISA | N/A | Yes | 2010 | [127] |
†
Includes independent validation set.
BBIA: Bead-based immunoassay; CT: Classification trees; LR: Logistic regression; MDA: Mixture discriminant analysis; MMC: Metropolis-Monte Carlo algorithm; MS: Mass spectroscopy; N/A: Not applicable; SI: Symptom index; SN: Sensitivity; SP: Specificity; SVM: Support vector machine.